CANA and GLP-1s have demonstrated weight loss (WL) in patients with type 2 diabetes mellitus (T2DM) in clinical trials. We compared the effects of CANA vs. GLP-1s on BW outcomes in routine practice using claims and electronic health record data from the U.S. Optum integrated database for adults with T2DM and ≥1 prescription claim for CANA or any GLP-1 from 1/1/13-3/31/15. BW outcomes and achievement of clinically significant WL ≥5% were assessed in matched patients with both ≥1 BW measurement during baseline (BL) and >31 days post-index. Inverse probability of treatment weighting (IPTW) accounted for differences in BL covariates. Weighted Cox regression was used to examine the hazard ratio (HR) and 95% confidence interval (CI) of WL ≥5%. After IPTW, covariates were balanced between cohorts except for BL BMI (CANA: n = 213; GLP-1: n = 235). Significant differences in BW were seen in the CANA vs. GLP-1 cohort over 9 months of follow-up (Figure). CANA cohort patients were more likely to achieve WL ≥5% (HR 1.93; 95% CI: 1.40-2.66) with a significantly longer duration at WL ≥5% (133 vs. 103 days; P = 0.01) than GLP-1 cohort patients.

In summary, superior WL of >9 kg at 9 months, >17% more patients achieving WL ≥5%, and longer duration of WL ≥5% as seen in the CANA vs. GLP-1 cohort may have important clinical implications due to links between BW reduction and other clinical/economic outcomes.

graphic
View largeDownload slide
Disclosure

C.I. Coleman: Research Support; Self; Janssen Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc. W.H. Herman: Other Relationship; Self; Merck Sharp & Dohme Corp., Lexicon Pharmaceuticals, Inc.. Consultant; Self; Janssen Scientific Affairs, LLC.. Research Support; Spouse/Partner; Nestlé. Other Relationship; Self; American Diabetes Association. Advisory Panel; Self; National Committee for Quality Assurance (NCQA). S. Pandya: Other Relationship; Self; Janssen Scientific Affairs, LLC. L. Wang: Other Relationship; Self; Janssen Scientific Affairs, LLC.. O. Baser: None. J. Cai: Employee; Self; Janssen Scientific Affairs, LLC. B. Bookhart: Employee; Self; Janssen Scientific Affairs, LLC..

© 2018 by the American Diabetes Association.
2018
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.